Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
In Ankleshwar, feisty MSMEs that survived the Chinese onslaught say that the fight against red tapism is harder
Bharuch is booming on the back of great roads, ports and a powered-up electrical grid